Disclosure under regulation 30 of Listing Regulations - Board of Directors approved an unsecured loan to Hester Biosciences Africa Limited, Foreign wholly-owned subsidiary of the Company.

5 November 2026 To, To, BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Dalal Street, Bandra - Kurla Complex, Mumbai 400 001 Bandra (E), Mumbai 400 051 Scrip Code: 524669 Symbol: HESTERBIO Dear Sir/ Madam: Subject: Outcome of Board Meeting and submission of unaudited Standalone and Consolidated Financial Results for the quarter and six months period ended 30 September 2026 This is with reference to our letter dated 27 October 2026 intimating the date of the Board Meeting for consideration of the standalone and consolidated financial results for the quarter and six months period ended 30 September 2026. Pursuant to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that Board of Directors, in their Meeting held today, have approved: 1. Unaudited Standalone and Consolidated Financial Results for the quarter and six months period ended 30 September 2026, as recommended by Audit Committee. 2. Unsecured loan of an aggregate amount of USD 1 million to Hester Biosciences Africa Limited (“Hester Africa”), foreign wholly-owned subsidiary in Tanzania, in one or more tranches. The loan is being extended for business and general corporate purposes, working capital requirement etc., subject to compliance with the applicable laws. We attach herewith: 1. The approved unaudited standalone and consolidated financial results and limited review reports 2. A Press Release issued in this regard 3. The details in this regard, pursuant to Regulation 30 of the Listing Regulations read with SEBI Master Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30 January 2026, is enclosed herewith as Annexure A. We will be publishing an extract of the results in the newspaper as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Board Meeting commenced at 10:30 a.m. (IST) and concluded at 11:05 a.m. (IST). You are requested to take the above information on your record. Sincerely For Hester Biosciences Limited Vinod Mali Company Secretary & Compliance Officer Enclosure: As above Annexure A The details as required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“Listing Regulations”) read with the SEBI Master Circular No. SEBI/HO/49/14/14(7)2025-CFD- POD2/I/3762/2026 dated 30 January 2026, are as under: Sr. Particulars Details 1 Name(s) of parties with whom the Lender: Hester Biosciences Limited, India agreement is entered Borrower: Hester Biosciences Africa Limited (Foreign Wholly-owned Subsidiary Company) 2 Purpose of entering into the Unsecured loan of an aggregate amount of USD 1 million, in agreement one or more tranches. The loan is being extended for business and general corporate purposes, working capital requirement etc., subject to compliance with the applicable laws. 3 Size of agreement Aggregate amount of USD 1 million, in one or more tranches 4 Shareholding, if any, in the entity The Company holds 100% stake in Hester Biosciences Africa with whom the agreement is Limited (“Hester Africa”). executed 5 Significant terms of the agreement • Interest Rate: 9% per annum (in brief) special rights like right to • Tenure: 3 (Three) years from first drawdown appoint directors, first right to share • Purpose: Hester Africa shall utilise the Loan amount for subscription in case of issuance of business and general corporate purposes, working shares, right to restrict any change in capital requirement etc. as permitted under applicable capital structure etc. laws. • Security: Loan is unsecured by nature • Special Rights: No special rights such as right to appoint directors, pre-emptive rights on share subscription, or restrictions on changes in capital structure are conferred under this agreement 6 a) Whether, the said parties are Hester Africa is a wholly-owned subsidiary of the Company, related to promoter/promoter hence the aforesaid transaction falls under the purview of group/ group companies in any Related Party Transactions as per the provisions of the manner. If yes, nature of Listing Regulations. relationship The transaction is between holding Company and wholly- b) Whether the transaction would owned subsidiary of the Company. Therefore, it is exempted fall within related party under Regulation 23(5)(b) of the Listing Regulations. transactions? If yes, whether the same is done at “arm’s length Further, the promoter / promoter group / group companies of the Company do not have any interest in the said transaction. The said transaction is at arm’s length basis. 7 In case of issuance of shares to the Not Applicable parties, details of issue price, class of shares issued 8 In case of loan agreements, details Lender: Hester Biosciences Limited, India of lender/borrower, nature of the loan, total amount of loan Borrower: Hester Biosciences Africa Limited granted/taken, total amount outstanding, date of execution of Nature of Loan: Unsecured Loan the loan agreement/sanction letter, details of the security provided to Total amount of loan: Aggregate amount of USD 1 million, in the lenders / by the borrowers for one or more tranches such loan or in case outstanding loans lent to a party or borrowed Date of execution of Loan Agreement: Expected on or before from a party become material on a 15 November 2026 cumulative basis Details of security provided to lender: Nil Amount of loan outstanding as on date of disclosure: Nil Other terms: as per loan agreement executed 9 Any other disclosures related to Not Applicable such agreements, viz., details of nominee on the board of directors of the listed entity, potential conflict of interest arising out of such agreements 10 In case of termination or Not Applicable amendment of agreement, listed entity shall disclose additional details to the stock exchange(s): a) name of parties to the agreement; b) nature of the agreement; c) date of execution of the agreement; d) d) details of amendment and impact thereof or reasons of termination and impact thereof. STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30 SEPTEMBER 2026 Amount in INR Million Quarter Ended Six Months Period Ended Year Ended 30 30 30 30 30 31 Sr. Particulars September June September September September March No. 2026 2026 2025 2026 2025 2026 Unaudited Unaudited Unaudited Unaudited Unaudited Audited Income 1 Revenue from Operations 8 29.28 7 26.60 6 45.79 1 ,555.88 1 ,280.69 2 ,921.36 2 Other Income 1 6.75 1 6.83 1 4.75 3 3.58 2 4.21 7 6.35 Total income 846.03 743.43 660.54 1,589.46 1,304.90 2,997.71 3 Expenses (a)Cost of material consumed 1 35.06 1 07.92 9 7.15 2 42.98 1 83.97 4 62.23 (b)Purchases of stock-in-trade 7 0.38 5 5.16 7 8.40 1 25.54 1 67.66 3 94.38 (c)Change in inventories of finished goods, ( 26.54) ( 3.48) 3 2.10 ( 30.02) 5 0.83 ( 36.93) traded goods and work in progress (d)Employee benefits expense 1 34.98 1 31.81 1 30.16 2 66.79 2 62.61 5 31.74 (e)Finance cost 1 6.97 1 3.64 1 2.72 3 0.61 2 1.77 7 1.69 (f)Depreciation and amortisation expense 4 9.53 4 9.18 2 2.01 9 8.71 4 3.65 1 02.52 (g)Other expenses 2 42.26 1 91.68 1 89.18 4 33.94 3 72.71 8 45.22 Total expenses 6 22.64 5 45.91 5 61.72 1 ,168.55 1 ,103.20 2 ,370.85 4 Profit before exceptional items and tax 2 23.39 1 97.52 98.82 420.91 201.70 626.86 5 Exceptional items (Refer Note 4) - - - - - 69.96 6 Profit before tax 223.39 197.52 98.82 420.91 201.70 696.82 7 Tax Expense Current tax 5 7.82 4 5.57 2 4.76 1 03.39 4 3.14 1 44.64 Tax Adjustment of earlier years - - 0 .05 - 0 .05 0 .02 Deferred tax ( 1.03) 4 .84 1 .92 3 .81 8 .04 3 1.16 Total tax expense 5 6.79 5 0.41 2 6.73 107.20 51.23 175.82 8 Profit after exceptional item and tax 166.60 147.11 72.09 313.71 150.47 521.00 9 Other Comprehensive Income Items that will not be reclassified to Profit or Loss Remeasurement Loss on Defined Benefit ( 0.34) - ( 1.22) ( 0.34) ( 2.43) ( 0.67) Plans Income tax impact 0 .08 - 0 .30 0 .08 0 .61 [Showing first 8,000 characters — download PDF for full document]